BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies

被引：40

作者：

Zhong, Jingqin ^{[1
]}

Yan, Wangjun ^{[1
]}

Wang, Chunmeng ^{[1
]}

Liu, Wanlin ^{[1
]}

Lin, Xinyi ^{[1
]}

Zou, Zijian ^{[1
]}

Sun, Wei ^{[1
]}

Chen, Yong ^{[1
]}

机构：

[1] Fudan Univ, Shanghai Canc Ctr, Dept Musculoskeletal Oncol, 270 Dongan Rd, Shanghai, Peoples R China

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2022年 / 23卷 / 11期

关键词：

Melanoma; BRAF mutation; BRAF inhibitor; Targeted therapy; Resistance mechanism; Combination therapy; ACQUIRED-RESISTANCE; MEK INHIBITION; ADAPTIVE RESISTANCE; CELL-DEATH; VEMURAFENIB; COMBINATION; DABRAFENIB; MACROPHAGES; TRAMETINIB; EXPRESSION;

D O I：

10.1007/s11864-022-01006-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Opinion statement Melanoma is caused by a variety of somatic mutations, and among these mutations, BRAF mutation occurs most frequently and has routinely been evaluated as a critical diagnostic biomarker in clinical practice. The introduction of targeted agents for BRAF-mutant melanoma has significantly improved overall survival in a large proportion of patients. However, there is BRAF inhibitor resistance in most patients, and its mechanisms are complicated and need further clarification. Additionally, treatment approaches to overcome resistance have evolved rapidly, shifting from monotherapy to multimodality treatment, which has dramatically improved patient outcomes in clinical trials and practice. This review highlights the mechanisms of BRAF inhibitor resistance in melanoma and discusses the current state of its therapeutic approaches that can be further explored in clinical practice.

引用

页码：1503 / 1521

页数：19

共 98 条

[1] Mutant-selective degradation by BRAF-targeting PROTACs [J].

Alabi, Shanique ;

Jaime-Figueroa, Saul ;

Yao, Zhan ;

Gao, Yijun ;

Hines, John ;

Samarasinghe, Kusal T. G. ;

Vogt, Lea ;

Rosen, Neal ;

Crews, Craig M. .

NATURE COMMUNICATIONS, 2021, 12 (01)

[2] Continuous versus intermittent BRAF and MEK inhibition in patients withBRAF-mutated melanoma: a randomized phase 2 trial [J].

Algazi, Alain P. ;

Othus, Megan ;

Daud, Adil, I ;

Lo, Roger S. ;

Mehnert, Janice M. ;

Thach-Giao Truong ;

Conry, Robert ;

Kendra, Kari ;

Doolittle, Gary C. ;

Clark, Joseph, I ;

Messino, Michael J. ;

Moore, Dennis F., Jr. ;

Lao, Christopher ;

Faller, Bryan A. ;

Govindarajan, Rangaswamy ;

Harker-Murray, Amy ;

Dreisbach, Luke ;

Moon, James ;

Grossmann, Kenneth F. ;

Ribas, Antoni .

NATURE MEDICINE, 2020, 26 (10) :1564-+

[3] Epigenetic alterations in chronic disease focusing on Behcet's disease: Review [J].

Alipour, Shahriar ;

Nouri, Mohammad ;

Sakhinia, Ebrahim ;

Samadi, Nasser ;

Roshanravan, Neda ;

Ghavami, Abed ;

Khabbazi, Alireza .

BIOMEDICINE & PHARMACOTHERAPY, 2017, 91 :526-533

[4] Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma [J].

Almeida, Filipe V. ;

Douglass, Stephen M. ;

Fane, Mitchell E. ;

Weeraratna, Ashani T. .

PIGMENT CELL & MELANOMA RESEARCH, 2019, 32 (02) :237-247

[5] WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors [J].

Anastas, Jamie N. ;

Kulikauskas, Rima M. ;

Tamir, Tigist ;

Rizos, Helen ;

Long, Georgina V. ;

von Euw, Erika M. ;

Yang, Pei-Tzu ;

Chen, Hsiao-Wang ;

Haydu, Lauren ;

Toroni, Rachel A. ;

Lucero, Olivia M. ;

Chien, Andy J. ;

Moon, Randall T. .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (07) :2877-2890

[6] Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma [J].

Ascierto, Paolo A. ;

Dummer, Reinhard ;

Gogas, Helen J. ;

Flaherty, Keith T. ;

Arance, Ana ;

Mandala, Mario ;

Liszkay, Gabriella ;

Garbe, Claus ;

Schadendorf, Dirk ;

Krajsova, Ivana ;

Gutzmer, Ralf ;

de Groot, Jan Willem B. ;

Loquai, Carmen ;

Gollerkeri, Ashwin ;

Pickard, Michael D. ;

Robert, Caroline .

EUROPEAN JOURNAL OF CANCER, 2020, 126 :33-44

[7] CRAF R391W is a melanoma driver oncogene [J].

Atefi, Mohammad ;

Titz, Bjoern ;

Tsoi, Jennifer ;

Avramis, Earl ;

Le, Allison ;

Ng, Charles ;

Lomova, Anastasia ;

Lassen, Amanda ;

Friedman, Michael ;

Chmielowski, Bartosz ;

Ribas, Antoni ;

Graeber, Thomas G. .

SCIENTIFIC REPORTS, 2016, 6

[8] Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma [J].

Atefi, Mohammad ;

Avramis, Earl ;

Lassen, Amanda ;

Wong, Deborah J. L. ;

Robert, Lidia ;

Foulad, David ;

Cerniglia, Michael ;

Titz, Bjoern ;

Chodon, Thinle ;

Graeber, Thomas G. ;

Comin-Anduix, Begonya ;

Ribas, Antoni .

CLINICAL CANCER RESEARCH, 2014, 20 (13) :3446-3457

[9] Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway [J].

Atefi, Mohammad ;

von Euw, Erika ;

Attar, Narsis ;

Ng, Charles ;

Chu, Connie ;

Guo, Deliang ;

Nazarian, Ramin ;

Chmielowski, Bartosz ;

Glaspy, John A. ;

Comin-Anduix, Begonya ;

Mischel, Paul S. ;

Lo, Roger S. ;

Ribas, Antoni .

PLOS ONE, 2011, 6 (12)

[10] Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib [J].

Atzori, Maria Grazia ;

Ceci, Claudia ;

Ruffini, Federica ;

Trapani, Mauro ;

Barbaccia, Maria Luisa ;

Tentori, Lucio ;

D'Atri, Stefania ;

Lacal, Pedro Miguel ;

Graziani, Grazia .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (01) :465-475

← 1 2 3 4 5 6 7 8 9 10 →